221 related articles for article (PubMed ID: 26829597)
1. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
[TBL] [Abstract][Full Text] [Related]
3. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
Ther Drug Monit; 2019 Feb; 41(1):86-90. PubMed ID: 30489548
[TBL] [Abstract][Full Text] [Related]
5. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
[TBL] [Abstract][Full Text] [Related]
6. A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study.
Nagai G; Mihara K; Kagawa S; Nakamura A; Suzuki T; Nemoto K; Kondo T
Neuropsychobiology; 2017; 76(4):187-192. PubMed ID: 29961057
[TBL] [Abstract][Full Text] [Related]
7. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
[TBL] [Abstract][Full Text] [Related]
8. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
9. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
[TBL] [Abstract][Full Text] [Related]
10. An open study of lamotrigine in refractory bipolar depression.
Kusumakar V; Yatham LN
Psychiatry Res; 1997 Sep; 72(2):145-8. PubMed ID: 9335206
[TBL] [Abstract][Full Text] [Related]
11. [Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression].
Krawczyk K; Rybakowski J
Psychiatr Pol; 2012; 46(4):585-98. PubMed ID: 23214161
[TBL] [Abstract][Full Text] [Related]
12. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
[TBL] [Abstract][Full Text] [Related]
13. Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder.
Kaye NS; Graham J; Roberts J; Thompson T; Nanry K
J Clin Psychopharmacol; 2007 Aug; 27(4):387-91. PubMed ID: 17679147
[TBL] [Abstract][Full Text] [Related]
14. Valproate as a risk factor for lamotrigine discontinuation.
Abe Y; Yasugawa S; Miyamoto K; Terao T
J Affect Disord; 2013 Sep; 150(3):1197-9. PubMed ID: 23747209
[TBL] [Abstract][Full Text] [Related]
15. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
Schindler F; Anghelescu IG
Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
[TBL] [Abstract][Full Text] [Related]
16. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
Anand A; Gunn AD; Barkay G; Karne HS; Nurnberger JI; Mathew SJ; Ghosh S
Bipolar Disord; 2012 Feb; 14(1):64-70. PubMed ID: 22329473
[TBL] [Abstract][Full Text] [Related]
17. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression.
Ahn YM; Nam JY; Culver JL; Marsh WK; Bonner JC; Ketter TA
Ann Clin Psychiatry; 2011 Feb; 23(1):17-24. PubMed ID: 21318192
[TBL] [Abstract][Full Text] [Related]
19. Lamotrigine use in geriatric patients with bipolar depression.
Robillard M; Conn DK
Can J Psychiatry; 2002 Oct; 47(8):767-70. PubMed ID: 12420655
[TBL] [Abstract][Full Text] [Related]
20. Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting.
Woo YS; Bahk WM; Pae CU; Jeong JH; Koo BH; Jon DI; Lee JG; Kim MD
Asia Pac Psychiatry; 2014 Sep; 6(3):334-41. PubMed ID: 24038834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
